Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150.

Chen S, Ou R, Tang J, Deng X, Wu Y, van Velkinburgh JC, Ni B, Xu Y.

Cancer Epidemiol. 2013 Apr;37(2):172-8. doi: 10.1016/j.canep.2012.10.005.

PMID:
23127963
2.

Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice.

Ren F, Xu Y, Mao L, Ou R, Ding Z, Zhang X, Tang J, Li B, Jia Z, Tian Z, Ni B, Wu Y.

Cancer Biol Ther. 2010 Jan;9(2):134-41.

PMID:
19901562
3.

Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.

Jia Y, Yin Y, Duan F, Fu H, Hu M, Gao Y, Pan Z, Jiao X.

Int J Mol Med. 2012 Dec;30(6):1335-42. doi: 10.3892/ijmm.2012.1136.

PMID:
23027427
4.

The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.

Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S.

Scand J Immunol. 2012 Jan;75(1):27-37. doi: 10.1111/j.1365-3083.2011.02620.x.

5.

HSP70 modified response against HPV based tumor.

Farzanehpour M, Soleimanjahi H, Hassan ZM, Amanzadeh A, Ghaemi A, Fazeli M.

Eur Rev Med Pharmacol Sci. 2013 Jan;17(2):228-34.

6.

Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.

Li YL, Qiu XH, Shen C, Liu JN, Zhang J.

Oncol Rep. 2010 Nov;24(5):1323-9.

PMID:
20878127
7.

Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.

Cheng WF, Chang MC, Sun WZ, Jen YW, Liao CW, Chen YY, Chen CA.

PLoS One. 2013 Sep 13;8(9):e71216. doi: 10.1371/journal.pone.0071216.

8.

A novel "priming-boosting" strategy for immune interventions in cervical cancer.

Liao S, Zhang W, Hu X, Wang W, Deng D, Wang H, Wang C, Zhou J, Wang S, Zhang H, Ma D.

Mol Immunol. 2015 Apr;64(2):295-305. doi: 10.1016/j.molimm.2014.12.007.

PMID:
25575128
9.

Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.

Rahimian S, Fransen MF, Kleinovink JW, Christensen JR, Amidi M, Hennink WE, Ossendorp F.

J Control Release. 2015 Apr 10;203:16-22. doi: 10.1016/j.jconrel.2015.02.006.

PMID:
25660830
11.
12.

Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

J Virol. 2009 Jul;83(13):6779-89. doi: 10.1128/JVI.02443-08.

13.

A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer.

Sharma C, Khan MA, Mohan T, Shrinet J, Latha N, Singh N.

Immunol Res. 2014 Jan;58(1):132-8. doi: 10.1007/s12026-013-8447-2.

PMID:
24174302
14.

Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.

Grasso F, Negri DR, Mochi S, Rossi A, Cesolini A, Giovannelli A, Chiantore MV, Leone P, Giorgi C, Cara A.

Int J Cancer. 2013 Jan 15;132(2):335-44. doi: 10.1002/ijc.27676.

15.

HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo.

Liao SJ, Deng DR, Zeng D, Zhang L, Hu XJ, Zhang WN, Li L, Jiang XF, Wang CY, Zhou JF, Wang SX, Zhang HW, Ma D.

J Huazhong Univ Sci Technolog Med Sci. 2013 Oct;33(5):735-42. doi: 10.1007/s11596-013-1189-5.

PMID:
24142729
16.

A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.

Granadillo M, Vallespi MG, Batte A, Mendoza O, Soria Y, Lugo VM, Torrens I.

Vaccine. 2011 Jan 29;29(5):920-30. doi: 10.1016/j.vaccine.2010.11.083.

PMID:
21145912
17.

Induction of antitumor immunity against cervical cancer by protein HPV-16 E7 in fusion with ricin B chain in tumor-bearing mice.

Sadraeian M, Rasoul-Amini S, Mansoorkhani MJ, Mohkam M, Ghoshoon MB, Ghasemi Y.

Int J Gynecol Cancer. 2013 Jun;23(5):809-14. doi: 10.1097/IGC.0b013e3182907989.

PMID:
23574882
18.

A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease.

Bungener L, de Mare A, de Vries-Idema J, Sehr P, van der Zee A, Wilschut J, Daemen T.

Antivir Ther. 2006;11(6):717-27.

PMID:
17310816
19.

A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.

Demurtas OC, Massa S, Ferrante P, Venuti A, Franconi R, Giuliano G.

PLoS One. 2013 Apr 23;8(4):e61473. doi: 10.1371/journal.pone.0061473.

20.

Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation.

Wu CY, Monie A, Pang X, Hung CF, Wu TC.

J Biomed Sci. 2010 Nov 22;17:88. doi: 10.1186/1423-0127-17-88.

Items per page

Supplemental Content

Support Center